OUR GOAL - To lead the way in precision gene therapies for neurological disorders
ABOUT US
Avrion Therapeutics was founded in 2020 based on 10+ years of research from the Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL) led by the groups of Dr. Bernard Schneider and Prof. Brian McCabe.
Our immediate mission is to develop proof of clinical efficacy for AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), associated with aberrations of the protein Superoxide Dismutase 1 - SOD1.
Our immediate mission is to develop proof of clinical efficacy for AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), associated with aberrations of the protein Superoxide Dismutase 1 - SOD1.
Avrion Therapeutics was founded in 2020 based on 10+ years of research from the Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL) led by the groups of Dr. Bernard Schneider and Prof. Brian McCabe.
Our immediate mission is to develop proof of clinical efficacy for AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), associated with aberrations of the protein Superoxide Dismutase 1 - SOD1.
Our immediate mission is to develop proof of clinical efficacy for AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), associated with aberrations of the protein Superoxide Dismutase 1 - SOD1.
